stockrow
Saturday 7 November 2026
Export NAUT’s income statement to Excel — free account
Nautilus Biotechnology, Inc.
NAUT Healthcare Biotechnology
- EPS
- −11.7%
- Free cash flow
- −28.6%
Quarter to September 2026, against a year earlier
2.23
0.08
+3.72%
Follow NAUT
Alert me
| Sep '26 | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | — | — |
+8 more quarters Free account |
P/S ratio |
0.00 | 0.00 | — | — | |
P/FCF ratio |
0.00 | 0.00 | — | — | |
P/Operating CF |
(13.60) | (17.32) | — | — | |
P/B ratio |
1.55 | 1.81 | — | — | |
Price to Tangible BV |
1.55 | 1.81 | — | — | |
EV/Sales |
0.00 | 0.00 | — | — | |
EV/EBITDA |
0.00 | 0.00 | — | — | |
EV/Operating CF |
(1.79) | (3.06) | — | — | |
EV/FCF |
(1.71) | (2.96) | — | — | |
Quick Ratio |
8.87 | 9.73 | 11.49 | 13.00 | |
Current Ratio |
9.25 | 10.14 | 11.85 | 13.33 | |
Net Debt/EBITDA |
5.62 | 5.81 | 6.51 | 7.41 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.85 | 0.95 | 0.89 | 0.90 | |
Capex/Depreciation |
(1.09) | (0.35) | (0.36) | (0.17) | |
Research and Development Expense of Revenue |
4,348.72% | 5,059.47% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
2,893.59% | 3,328.95% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
552.14% | 609.47% | 0.00% | 0.00% | |
Graham Net Nets |
0.32 | 0.23 | — | — | |
Graham Number |
0.00 | 0.00 | — | — | |
Earnings Yield |
(32.60%) | (24.06%) | — | — | |
Free Cash Flow Yield |
(30.52%) | (21.81%) | — | — | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.10) | (0.11) | (0.10) | (0.10) | |
Capex per Share |
(0.01) | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.12) | (0.11) | (0.11) | (0.10) | |
Cash per Share |
0.68 | 0.66 | 0.76 | 0.82 | |
Shareholders Equity per Share |
0.92 | 1.03 | 1.14 | 1.24 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.92 | 1.03 | 1.14 | 1.24 | |
Free Cash Flow |
(14.73) | (14.18) | (13.61) | (12.62) | |
Working Capital |
80.48 | 78.99 | 90.49 | 98.01 | |
Capital Expenditures |
(1.44) | (0.45) | (0.51) | (0.24) | |
Net Current Asset Value |
57.87 | 55.16 | 65.47 | 71.82 | |
EV/EBIT |
0.00 | 0.00 | — | — | |
Capex to Sales |
6.18 | 2.39 | 0.00 | 0.00 | |
Price to Operating Income |
0.00 | 0.00 | — | — | |
| Other line items | |||||
Average Payables |
1.08 | 1.03 | 1.01 | 0.97 | |
Average Assets |
174.92 | 188.38 | 202.73 | 216.93 | |
Average Common Equity |
142.85 | 156.10 | 169.43 | 182.85 |
Columns are period end dates · fundamentals updated 2 Nov 2026